atorvastatin has been researched along with Liver Dysfunction in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (71.43) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, CH; Chang, YC; Chuang, LM; Lee, YC; Lin, JW; Liu, YC | 1 |
| Alexandropoulos, D; Arkadopoulos, N; Bazigos, GV; Doulamis, IP; Kondi-Pafiti, A; Konstantopoulos, P; Kotsis, T; Perrea, DN; Smyrniotis, V; Tragotsalou, N; Tzani, A | 1 |
| González-Gallego, J; Mauriz, JL; Tuñón, MJ | 1 |
| Bonkovsky, HL; Russo, MW; Scobey, M | 1 |
| Becx, MC; Kuypers, KC; Seldenrijk, CA; Stolk, MF | 1 |
| Andrade, RJ; Barriocanal, A; Borraz, Y; Costa, J; Durán, JA; Fernández, MC; García-Cortés, M; García-Muņoz, B; Guarner, C; Hidalgo, R; Kaplowitz, N; Lucena, MI; Muņoz-Yagüe, T; Pachkoria, K; Pelaez, G; Planas, R; Rodrigo, L; Romero-Gomez, M; Salmerón, J | 1 |
| Alsheikh-Ali, AA; Karas, RH | 1 |
2 review(s) available for atorvastatin and Liver Dysfunction
| Article | Year |
|---|---|
Apoptotic signaling pathways as a target for the treatment of liver diseases.
Topics: Animals; Apoptosis; Atorvastatin; Gliotoxin; Heptanoic Acids; Humans; Liver Diseases; Molecular Conformation; Pyrroles; Signal Transduction; Ursodeoxycholic Acid | 2008 |
Drug-induced liver injury associated with statins.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Autoimmunity; Biomarkers; Biopsy; Chemical and Drug Induced Liver Injury; Chronic Disease; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Liver; Liver Diseases; Male; Middle Aged; Practice Guidelines as Topic; Pyrroles; Risk Assessment; Treatment Outcome; Young Adult | 2009 |
5 other study(ies) available for atorvastatin and Liver Dysfunction
| Article | Year |
|---|---|
Severe hepatic injury associated with different statins in patients with chronic liver disease: a nationwide population-based cohort study.
Topics: Adult; Aged; Atorvastatin; Chemical and Drug Induced Liver Injury; Chronic Disease; Cohort Studies; Follow-Up Studies; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Liver Diseases; Male; Middle Aged; Pyrroles; Risk; Severity of Illness Index; Taiwan; Time Factors | 2015 |
Protective effects of N-acetylcystein and atorvastatin against renal and hepatic injury in a rat model of intestinal ischemia-reperfusion.
Topics: Acetylcysteine; Acute Kidney Injury; Animals; Antioxidants; Atorvastatin; Drug Therapy, Combination; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intestines; Kidney Function Tests; Liver Diseases; Liver Function Tests; Male; Protective Agents; Rats; Rats, Wistar; Reperfusion Injury | 2017 |
Severe hepatic side effects of ezetimibe.
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Liver Diseases; Male; Middle Aged; Pyrroles; Transaminases | 2006 |
Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin-Potassium Clavulanate Combination; Atorvastatin; Azepines; Captopril; Cardiovascular Agents; Central Nervous System Agents; Chemical and Drug Induced Liver Injury; Chronic Disease; Disease Progression; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Heptanoic Acids; Humans; Liver; Liver Diseases; Male; Middle Aged; Pyrroles; Registries; Spain | 2006 |
Safety of lovastatin/extended release niacin compared with lovastatin alone, atorvastatin alone, pravastatin alone, and simvastatin alone (from the United States Food and Drug Administration adverse event reporting system).
Topics: Adverse Drug Reaction Reporting Systems; Atorvastatin; Chemical and Drug Induced Liver Injury; Drug Prescriptions; Drug Therapy, Combination; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Liver Diseases; Lovastatin; Niacin; Pravastatin; Prevalence; Pyrroles; Retrospective Studies; Rhabdomyolysis; Risk Factors; Simvastatin; United States; United States Food and Drug Administration | 2007 |